. Author manuscript; available in PMC: 2012 Jan 1.

Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2010 Nov 10;20(1):91–100. doi: 10.1158/1055-9965.EPI-10-0349

Table 2.

Abstinence rates at follow-up

Continuous Abstinence (weeks 1–4)
	Treatments
	Snus(n=51)		Taboka (n=52)		NRT (n=27)		p-value
	# abstinent	%	# abstinent	%	# abstinent	%	p-value
¹CO Verified	22	43.1	17	32.7	11	40.7	0.554

CO Verified Point Prevalence Abstinence
	Treatments
	Snus (n=51)		Taboka (n=52)		NRT (n=27)
Visit	# abstinent	%	# abstinent	%	# abstinent	%	p-value
Week 4	29	56.9	22	42.3	15	55.6	0.299
Week 6 (1 week follow-up)	24	47.1	20	38.5	15	55.6	0.349
Week 16 (11 weeks follow-up)	16	31.4	12	23.1	9	33.3	0.537
CO and Cotinine Verified Point Prevalence Abstinence
	Treatments
	Snus (n=51)		Taboka (n=52)		NRT (n=27)
Visit	# abstinent	%	# abstinent	%	# abstinent	%	p-value
Week 6 (1 week follow-up)	14	27.5	12	23.1	8	29.6	0.76
Week 16 (11 weeks follow-up)	10	19.6	7	13.5	4	14.8	0.712